Pharmacogenetics of human immunodeficiency virus therapy

Host genetic factors influencing drug disposition and response to human immunodeficiency virus treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN81110147

Enrollment

900

Registered

2010-05-28

Start date

2007-04-24

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Infection

Interventions

Study A: This study is examining treatment response after starting or switching antiretroviral therapy according to genotype with the primary endpoint of a change in CD4 count and vira

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Study A: Recruitment from existing cohort studies Study B: 1. Aged greater than 18 years 2. Know HIV-seropositive 3. Receiving antiretroviral therapy 4. Having drug concentration measured

Exclusion criteria

Exclusion criteria: Study A: Recruitment from existing cohort studies Study B: 1. Aged less than 18 years 2. Not on antiretroviral therapy

Design outcomes

Primary

Measure	Time frame
Change in CD4 count and viral load, measured at 24 weeks, with secondary endpoints of viral load at 12 weeks and time to/proportion achieving undetectable viral load	—

Secondary

Measure	Time frame
1. Change in viral load at 12 weeks 2. Time to/proportion achieving undetectable viral load	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026